12/08/2017 04:58:00

ONE WEEK DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Booz Allen Hamilton Holding Corporation and Encourages Investors with Losses Exceeding $100,000 to Contact the Firm

Related content
12 Sep - 
Lawsuit for Investors in Booz Allen Hamilton Holding Co..
11 Aug - 
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Sharehold..
10 Aug - 
INVESTOR ALERT: Lundin Law PC Announces Securities Clas..

IRVINE, Calif., Aug. 11, 2017 (GLOBE NEWSWIRE) -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Booz Allen Hamilton Holding Corporation (“Booz Allen” or the “Company”) (NYSE:BAH). Investors who purchased or otherwise acquired Booz Allen shares from May 19, 2016 through June 15, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm before the August 18, 2017 lead plaintiff motion deadline.

If you purchased shares of Booz Allen during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.

According to the lawsuit, throughout the Class Period, Booz Allen made false and misleading statements and/or failed to disclose that: the Company engaged in improper accounting practices in its contracts with the U.S. government; that its revenues derived from services provided to the U.S. government were inflated and unsustainable; that the discovery of such conduct would subject the Company to heightened regulatory scrutiny, potential criminal sanctions, and endanger its business relationship with the government; and that as a result, Booz Allen’s public statements were materially false and misleading at all relevant times.

On June 15, 2017, Booz Allen revealed that on June 7, 2017, the Company’s wholly-owned subsidiary, Booz Allen Hamilton Inc., “was informed that the U.S. Department of Justice is conducting a civil and criminal investigation relating to certain elements of the Company’s cost accounting and indirect cost charging practices with the U.S. government.” When this information was announced, Booz Allen’s stock price dropped materially, which harmed investors according to the Complaint.

If you want to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may be considered Attorney Advertising in certain jurisdictions.

Contact

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Regulatory news

Alliance Trust PLC : Net Asset Value(s)

23/10/2017 13:14:06
ALLIANCE TRUST PLC                                    At the close of business on Friday 20 October 2017: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 778.5p -       including income, 787.1p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding inco..

Rathbones : Form 8.3 - [Clinigen Group PLC]

23/10/2017 10:58:08
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Rathbone Brothers PLC (b) Owner or controller of ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
H.B. Fuller Poised for Global Growth with Acquisition of Royal Adhesives & Sealants
2
Sequent Announces Two New Sequent Platform Versions
3
Simmons Reports Third Quarter 2017 Earnings
4
Novartis combination adjuvant therapy Tafinlar® + Mekinist® receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients
5
MEDIA ADVISORY: US Commerce Secretary Wilbur Ross to Hold Listening Session at National Minority Supplier Development Council Annual Conference

Related stock quotes

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
23 October 2017 18:07:41
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20171023.1 - EUROWEB7 - 2017-10-23 19:07:41 - 2017-10-23 18:07:41 - 1000 - Website: OKAY